- Query in any language with multilingual search
- Access EUR-Lex and EU Commission case law
- See relevant paragraphs highlighted instantly
Similar Documents
Explore similar documents to your case.We Found Similar Cases for You
Case C-181/24, Genmab: Request for a preliminary ruling from the Fővárosi Törvényszék (Hungary) lodged on 6 March 2024 - Genmab A/S
ECLI:EU:UNKNOWN:62024CN0181
62024CN0181
With us you find everything. Try it now!
I imagine what I want to write in my case, I write it in the search engine and I get exactly what I wanted. Thank you!
Valentina R., lawyer
Official Journal of the European Union
C series
—
C/2024/3059
13.5.2024
(Case C-181/24, Genmab)
(C/2024/3059)
Language of the case: Hungarian
Referring court
Parties to the main proceedings
Applicant: Genmab A/S
Other party: Szellemi Tulajdon Nemzeti Hivatala
Question referred
Must Article 3(b) and (d) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (1) be interpreted as meaning that a marketing authorisation predating the marketing authorisation appearing in the application for a supplementary protection certificate and referring to the same product must be regarded as the first marketing authorisation for the purposes of that regulation, even where that prior marketing authorisation was withdrawn prior to the submission of the application for the certificate?
Language of the case: Hungarian
ELI: http://data.europa.eu/eli/C/2024/3059/oj
ISSN 1977-091X (electronic edition)
—
* Language of the case: Hungarian.